179 related articles for article (PubMed ID: 21187514)
1. A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
Farkouh A; Ettlinger D; Schueller J; Georgopoulos A; Scheithauer W; Czejka M
Anticancer Res; 2010 Dec; 30(12):5207-11. PubMed ID: 21187514
[TBL] [Abstract][Full Text] [Related]
2. Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
Schreiber V; Kitzmueller M; Poxhofer M; Gintersdorfer S; Neudorfer C; Lichtneckert M; Dittrich C; Czejka M
Anticancer Res; 2014 Jul; 34(7):3371-6. PubMed ID: 24982342
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
Dennie TW; Fleming RA; Bowen CJ; Dar MM; Alberti D; Oliver K; Loconte N; Mulkerin D; Holen KD
Clin Colorectal Cancer; 2011 Mar; 10(1):57-62. PubMed ID: 21609937
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
Iqbal S; Lenz HJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
Farid M; Chowbay B; Chen X; Tan SH; Ramasamy S; Koo WH; Toh HC; Choo SP; Ong SY
Cancer Chemother Pharmacol; 2012 Jul; 70(1):141-50. PubMed ID: 22648745
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
[TBL] [Abstract][Full Text] [Related]
7. Rapid and simplified HPLC-UV method with on-line wavelengths switching for determination of capecitabine in human plasma.
Piórkowska E; Kaza M; Fitatiuk J; Szlaska I; Pawiński T; Rudzki PJ
Pharmazie; 2014 Jul; 69(7):500-5. PubMed ID: 25073394
[TBL] [Abstract][Full Text] [Related]
8. [A case of toxicity caused by drug interaction between capecitabine and phenytoin in patient with colorectal cancer].
Sakurai M; Kawahara K; Ueda R; Fukui E; Yamada R
Gan To Kagaku Ryoho; 2011 May; 38(5):841-3. PubMed ID: 21566450
[TBL] [Abstract][Full Text] [Related]
9. Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma.
Xu Y; Grem JL
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(1):273-85. PubMed ID: 12450548
[TBL] [Abstract][Full Text] [Related]
10. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
[TBL] [Abstract][Full Text] [Related]
11. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Chu E; Schulman KL; McKenna EF; Cartwright T
Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
[TBL] [Abstract][Full Text] [Related]
12. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
[TBL] [Abstract][Full Text] [Related]
13. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
Vainchtein LD; Rosing H; Schellens JH; Beijnen JH
Biomed Chromatogr; 2010 Apr; 24(4):374-86. PubMed ID: 19650151
[TBL] [Abstract][Full Text] [Related]
14. Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
Farkouh A; Schueller J; Scheithauer W; Czejka M
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):487-8. PubMed ID: 20557855
[No Abstract] [Full Text] [Related]
15. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
16. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
17. Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection.
Zufía L; Aldaz A; Giráldez J
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 809(1):51-8. PubMed ID: 15282093
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
19. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
Deenen MJ; Rosing H; Hillebrand MJ; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():30-40. PubMed ID: 23270936
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Farkouh A; Scheithauer W; Buchner P; Georgopoulos A; Schueller J; Gruenberger B; Czejka M
Anticancer Res; 2014 Jul; 34(7):3669-73. PubMed ID: 24982385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]